Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma

Marie Shimanuki, Yorihisa Imanishi, Yoichiro Sato, Nana Nakahara, Daisuke Totsuka, Emiri Sato, Sena Iguchi, Yasuo Sato, Keiko Soma, Yasutomo Araki, Seiji Shigetomi, Satoko Yoshida, Kosuke Uno, Yusuke Ogawa, Takehiro Tominaga, Yuichi Ikari, Junko Nagayama, Ayako Endo, Koshiro Miura, Takuya TomiokaHiroyuki Ozawa, Kaoru Ogawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Febrile neutropenia (FN) is the most serious hematologic toxicity of systemic chemotherapy. However, accurate prediction of FN development has been difficult because the risk varies largely depending on the chemotherapy regimen and various individual factors. Methods: We retrospectively analyzed diverse clinical factors including pretreatment hematological parameters to clarify the reliable predictors of FN development during chemotherapy with a docetaxel, cisplatin, and fluorouracil (TPF) regimen in patients with head and neck squamous cell carcinoma. Results: Among the 50 patients, grade ≥3 neutropenia, grade 4 neutropenia, and FN developed in 36 (72%), 21 (42%), and 12 (24%) patients, respectively. Multivariate logistic regression revealed that a pretreatment absolute monocyte count (AMC) < 370/mm3 is an independent predictor of TPF chemotherapy-induced FN (odds ratio=6.000, p=0.017). The predictive performance of the model combining AMC and absolute neutrophil count (ANC), in which the high-risk group was defined as having an AMC < 370/mm3 and/or ANC < 3500/mm3, was superior (area under the curve [AUC]=0.745) to that of the model with a cutoff for AMC alone (AUC=0.679). Conclusions: On the basis of our results, we recommend primary prophylactic use of granulocyte colony-stimulating factor and/or antibiotics selectively for patients predicted to be at high risk for TPF chemotherapy-induced FN.

Original languageEnglish
Pages (from-to)18970-18984
Number of pages15
JournalOncotarget
Volume9
Issue number27
DOIs
Publication statusPublished - 2018 Apr 10

Fingerprint

Febrile Neutropenia
Chemotherapy-Induced Febrile Neutropenia
Monocytes
Neutrophils
Drug Therapy
docetaxel
Neutropenia
Area Under Curve
Granulocyte Colony-Stimulating Factor
Fluorouracil
Cisplatin
Logistic Models
Odds Ratio
Anti-Bacterial Agents
Carcinoma, squamous cell of head and neck

Keywords

  • Febrile neutropenia
  • Head and neck squamous cell carcinoma
  • Monocyte count
  • Neutrophil count
  • TPF

ASJC Scopus subject areas

  • Oncology

Cite this

Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma. / Shimanuki, Marie; Imanishi, Yorihisa; Sato, Yoichiro; Nakahara, Nana; Totsuka, Daisuke; Sato, Emiri; Iguchi, Sena; Sato, Yasuo; Soma, Keiko; Araki, Yasutomo; Shigetomi, Seiji; Yoshida, Satoko; Uno, Kosuke; Ogawa, Yusuke; Tominaga, Takehiro; Ikari, Yuichi; Nagayama, Junko; Endo, Ayako; Miura, Koshiro; Tomioka, Takuya; Ozawa, Hiroyuki; Ogawa, Kaoru.

In: Oncotarget, Vol. 9, No. 27, 10.04.2018, p. 18970-18984.

Research output: Contribution to journalArticle

Shimanuki, M, Imanishi, Y, Sato, Y, Nakahara, N, Totsuka, D, Sato, E, Iguchi, S, Sato, Y, Soma, K, Araki, Y, Shigetomi, S, Yoshida, S, Uno, K, Ogawa, Y, Tominaga, T, Ikari, Y, Nagayama, J, Endo, A, Miura, K, Tomioka, T, Ozawa, H & Ogawa, K 2018, 'Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma', Oncotarget, vol. 9, no. 27, pp. 18970-18984. https://doi.org/10.18632/oncotarget.24863
Shimanuki, Marie ; Imanishi, Yorihisa ; Sato, Yoichiro ; Nakahara, Nana ; Totsuka, Daisuke ; Sato, Emiri ; Iguchi, Sena ; Sato, Yasuo ; Soma, Keiko ; Araki, Yasutomo ; Shigetomi, Seiji ; Yoshida, Satoko ; Uno, Kosuke ; Ogawa, Yusuke ; Tominaga, Takehiro ; Ikari, Yuichi ; Nagayama, Junko ; Endo, Ayako ; Miura, Koshiro ; Tomioka, Takuya ; Ozawa, Hiroyuki ; Ogawa, Kaoru. / Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma. In: Oncotarget. 2018 ; Vol. 9, No. 27. pp. 18970-18984.
@article{ca5fbb57b6d54e3d85d6263e6335009b,
title = "Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma",
abstract = "Background: Febrile neutropenia (FN) is the most serious hematologic toxicity of systemic chemotherapy. However, accurate prediction of FN development has been difficult because the risk varies largely depending on the chemotherapy regimen and various individual factors. Methods: We retrospectively analyzed diverse clinical factors including pretreatment hematological parameters to clarify the reliable predictors of FN development during chemotherapy with a docetaxel, cisplatin, and fluorouracil (TPF) regimen in patients with head and neck squamous cell carcinoma. Results: Among the 50 patients, grade ≥3 neutropenia, grade 4 neutropenia, and FN developed in 36 (72{\%}), 21 (42{\%}), and 12 (24{\%}) patients, respectively. Multivariate logistic regression revealed that a pretreatment absolute monocyte count (AMC) < 370/mm3 is an independent predictor of TPF chemotherapy-induced FN (odds ratio=6.000, p=0.017). The predictive performance of the model combining AMC and absolute neutrophil count (ANC), in which the high-risk group was defined as having an AMC < 370/mm3 and/or ANC < 3500/mm3, was superior (area under the curve [AUC]=0.745) to that of the model with a cutoff for AMC alone (AUC=0.679). Conclusions: On the basis of our results, we recommend primary prophylactic use of granulocyte colony-stimulating factor and/or antibiotics selectively for patients predicted to be at high risk for TPF chemotherapy-induced FN.",
keywords = "Febrile neutropenia, Head and neck squamous cell carcinoma, Monocyte count, Neutrophil count, TPF",
author = "Marie Shimanuki and Yorihisa Imanishi and Yoichiro Sato and Nana Nakahara and Daisuke Totsuka and Emiri Sato and Sena Iguchi and Yasuo Sato and Keiko Soma and Yasutomo Araki and Seiji Shigetomi and Satoko Yoshida and Kosuke Uno and Yusuke Ogawa and Takehiro Tominaga and Yuichi Ikari and Junko Nagayama and Ayako Endo and Koshiro Miura and Takuya Tomioka and Hiroyuki Ozawa and Kaoru Ogawa",
year = "2018",
month = "4",
day = "10",
doi = "10.18632/oncotarget.24863",
language = "English",
volume = "9",
pages = "18970--18984",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "27",

}

TY - JOUR

T1 - Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma

AU - Shimanuki, Marie

AU - Imanishi, Yorihisa

AU - Sato, Yoichiro

AU - Nakahara, Nana

AU - Totsuka, Daisuke

AU - Sato, Emiri

AU - Iguchi, Sena

AU - Sato, Yasuo

AU - Soma, Keiko

AU - Araki, Yasutomo

AU - Shigetomi, Seiji

AU - Yoshida, Satoko

AU - Uno, Kosuke

AU - Ogawa, Yusuke

AU - Tominaga, Takehiro

AU - Ikari, Yuichi

AU - Nagayama, Junko

AU - Endo, Ayako

AU - Miura, Koshiro

AU - Tomioka, Takuya

AU - Ozawa, Hiroyuki

AU - Ogawa, Kaoru

PY - 2018/4/10

Y1 - 2018/4/10

N2 - Background: Febrile neutropenia (FN) is the most serious hematologic toxicity of systemic chemotherapy. However, accurate prediction of FN development has been difficult because the risk varies largely depending on the chemotherapy regimen and various individual factors. Methods: We retrospectively analyzed diverse clinical factors including pretreatment hematological parameters to clarify the reliable predictors of FN development during chemotherapy with a docetaxel, cisplatin, and fluorouracil (TPF) regimen in patients with head and neck squamous cell carcinoma. Results: Among the 50 patients, grade ≥3 neutropenia, grade 4 neutropenia, and FN developed in 36 (72%), 21 (42%), and 12 (24%) patients, respectively. Multivariate logistic regression revealed that a pretreatment absolute monocyte count (AMC) < 370/mm3 is an independent predictor of TPF chemotherapy-induced FN (odds ratio=6.000, p=0.017). The predictive performance of the model combining AMC and absolute neutrophil count (ANC), in which the high-risk group was defined as having an AMC < 370/mm3 and/or ANC < 3500/mm3, was superior (area under the curve [AUC]=0.745) to that of the model with a cutoff for AMC alone (AUC=0.679). Conclusions: On the basis of our results, we recommend primary prophylactic use of granulocyte colony-stimulating factor and/or antibiotics selectively for patients predicted to be at high risk for TPF chemotherapy-induced FN.

AB - Background: Febrile neutropenia (FN) is the most serious hematologic toxicity of systemic chemotherapy. However, accurate prediction of FN development has been difficult because the risk varies largely depending on the chemotherapy regimen and various individual factors. Methods: We retrospectively analyzed diverse clinical factors including pretreatment hematological parameters to clarify the reliable predictors of FN development during chemotherapy with a docetaxel, cisplatin, and fluorouracil (TPF) regimen in patients with head and neck squamous cell carcinoma. Results: Among the 50 patients, grade ≥3 neutropenia, grade 4 neutropenia, and FN developed in 36 (72%), 21 (42%), and 12 (24%) patients, respectively. Multivariate logistic regression revealed that a pretreatment absolute monocyte count (AMC) < 370/mm3 is an independent predictor of TPF chemotherapy-induced FN (odds ratio=6.000, p=0.017). The predictive performance of the model combining AMC and absolute neutrophil count (ANC), in which the high-risk group was defined as having an AMC < 370/mm3 and/or ANC < 3500/mm3, was superior (area under the curve [AUC]=0.745) to that of the model with a cutoff for AMC alone (AUC=0.679). Conclusions: On the basis of our results, we recommend primary prophylactic use of granulocyte colony-stimulating factor and/or antibiotics selectively for patients predicted to be at high risk for TPF chemotherapy-induced FN.

KW - Febrile neutropenia

KW - Head and neck squamous cell carcinoma

KW - Monocyte count

KW - Neutrophil count

KW - TPF

UR - http://www.scopus.com/inward/record.url?scp=85045193544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045193544&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24863

DO - 10.18632/oncotarget.24863

M3 - Article

AN - SCOPUS:85045193544

VL - 9

SP - 18970

EP - 18984

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 27

ER -